CLAIM CARD
The evidence on aspirin's effect on frailty status is anchored in a post hoc secondary analysis of the Aspirin in Reducing Events in the Elderly (ASPREE) randomised clinical trial. The population comprised participants from the large-scale ASPREE cohort, and the trial's design allowed for assessment of frailty transition as a functional endpoint over the follow-up period. The study aimed to determine if a geroprotective effect of aspirin could be detected in this vulnerable subgroup.
Evidence grade: exploratory
Contradiction status: none
Publication: 4ff5f065-8b09-4580-9cbc-da14dbcaa1fa
Provenance: Derivation Web chain
Citation Support
source_1Flensted-Jensen 2025source_2Saeed 2026source_3Zhu 2026source_4Navarese 2026source_5Yan 2024